Century Therapeutics (IPSC) Current Deferred Revenue (2022 - 2024)

Century Therapeutics (IPSC) has 3 years of Current Deferred Revenue data on file, last reported at $109.2 million in Q4 2024.

• On a quarterly basis, Current Deferred Revenue rose 2396.89% year-over-year to $109.2 million in Q4 2024; TTM through Dec 2024 was $109.2 million, a 2396.89% increase from a year earlier, with the FY2024 full-year figure at $109.2 million, up 2396.89% from the prior year.
• Current Deferred Revenue for Q4 2024 stood at $109.2 million, up from $3.6 million in the prior quarter.
• Over the last five years, Current Deferred Revenue for IPSC reached as high as $109.2 million in Q4 2024 and fell as low as $3.6 million in Q3 2024.
• Historically, Current Deferred Revenue has averaged $14.4 million across 3 years, with a median of $6.4 million in 2022.
• Across the five-year window, Current Deferred Revenue slumped 48.87% in 2023 and soared 2396.89% in 2024, its largest moves.
• Year by year, Current Deferred Revenue stood at $7.2 million in 2022, then plunged by 38.89% to $4.4 million in 2023, then surged by 2396.89% to $109.2 million in 2024.
• Per Business Quant data, the three most recent Current Deferred Revenue figures were $109.2 million in Q4 2024, $3.6 million in Q3 2024, and $4.4 million in Q2 2024.